MA49061A - 4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES TO INCREASE CFTR ACTIVITY - Google Patents
4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES TO INCREASE CFTR ACTIVITYInfo
- Publication number
- MA49061A MA49061A MA049061A MA49061A MA49061A MA 49061 A MA49061 A MA 49061A MA 049061 A MA049061 A MA 049061A MA 49061 A MA49061 A MA 49061A MA 49061 A MA49061 A MA 49061A
- Authority
- MA
- Morocco
- Prior art keywords
- sulfonylaminocarbonylquinoline
- derivatives
- cftr activity
- increase cftr
- increase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491433P | 2017-04-28 | 2017-04-28 | |
| US201762569212P | 2017-10-06 | 2017-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49061A true MA49061A (en) | 2021-04-21 |
Family
ID=62165726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049061A MA49061A (en) | 2017-04-28 | 2018-04-30 | 4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES TO INCREASE CFTR ACTIVITY |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200055844A1 (en) |
| EP (1) | EP3615528B1 (en) |
| CA (1) | CA3061476A1 (en) |
| MA (1) | MA49061A (en) |
| WO (1) | WO2018201126A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ768373A (en) | 2014-10-06 | 2024-03-22 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20180093882A (en) | 2015-10-06 | 2018-08-22 | 프로테오스타시스 테라퓨틱스, 인크. | Compounds, compositions, and methods for CFTR regulation |
| WO2018064632A1 (en) | 2016-09-30 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| ES2837431T3 (en) | 2016-12-09 | 2021-06-30 | Vertex Pharma | Cystic fibrosis transmembrane conductance regulator modulators, pharmaceutical compositions, treatment methods, and processes for making the modulator |
| EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| KR102606188B1 (en) | 2017-08-02 | 2023-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | Process for producing pyrrolidine compounds |
| TWI719349B (en) | 2017-10-19 | 2021-02-21 | 美商維泰克斯製藥公司 | Crystalline forms and compositions of cftr modulators |
| KR20200097293A (en) | 2017-12-08 | 2020-08-18 | 버텍스 파마슈티칼스 인코포레이티드 | Method for producing a modulator of cystic fibrosis transmembrane conduction modulator |
| TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
| ES2939775T3 (en) | 2018-02-15 | 2023-04-26 | Vertex Pharma | Macrocycles as modulators of the transmembrane conductance regulator of cystic fibrosis, their pharmaceutical compositions, their use in the treatment of cystic fibrosis, and processes for making them |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2020006269A1 (en) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| IT201900000687A1 (en) * | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| TW202115092A (en) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | Modulators of cystic fibrosis transmembrane conductance regulator |
| TW202120517A (en) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | Process of making cftr modulators |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336264A (en) | 1980-06-19 | 1982-06-22 | Eli Lilly And Company | 1-Benzoyl-3-(isoxazolyl or benzisoxazolyl)-ureas and insecticidal use thereof |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| US8569899B2 (en) | 2009-12-30 | 2013-10-29 | Stmicroelectronics, Inc. | Device and method for alignment of vertically stacked wafers and die |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| ES2882807T3 (en) | 2011-09-16 | 2021-12-02 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| EP3591052B1 (en) | 2012-09-24 | 2023-08-30 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Restoration of the cftr function by splicing modulation |
| US9546176B2 (en) | 2012-11-20 | 2017-01-17 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic CFTR correctors |
| EP2922852A4 (en) | 2012-11-20 | 2016-05-25 | Discoverybiomed Inc | Small molecule cftr correctors |
| CN105307655B (en) | 2013-03-13 | 2019-05-03 | 弗拉特利发现实验室有限责任公司 | Pyridazinone compound and its be used to prepare treatment tumour shape fibrosis drug application |
| US9771327B2 (en) | 2013-03-13 | 2017-09-26 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
| WO2014144860A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| AU2014240026B2 (en) | 2013-03-15 | 2018-06-14 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| WO2014176553A1 (en) | 2013-04-26 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| JP2016517895A (en) | 2013-05-07 | 2016-06-20 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | Novel compounds for treating cystic fibrosis and pharmaceutical compositions thereof |
| KR20180093882A (en) * | 2015-10-06 | 2018-08-22 | 프로테오스타시스 테라퓨틱스, 인크. | Compounds, compositions, and methods for CFTR regulation |
-
2018
- 2018-04-30 WO PCT/US2018/030123 patent/WO2018201126A1/en active Application Filing
- 2018-04-30 US US16/609,076 patent/US20200055844A1/en not_active Abandoned
- 2018-04-30 MA MA049061A patent/MA49061A/en unknown
- 2018-04-30 EP EP18724750.7A patent/EP3615528B1/en active Active
- 2018-04-30 CA CA3061476A patent/CA3061476A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200055844A1 (en) | 2020-02-20 |
| EP3615528B1 (en) | 2022-02-16 |
| EP3615528A1 (en) | 2020-03-04 |
| WO2018201126A1 (en) | 2018-11-01 |
| CA3061476A1 (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49061A (en) | 4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES TO INCREASE CFTR ACTIVITY | |
| MA45397A (en) | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR | |
| MA41253A (en) | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR | |
| MA42488A (en) | COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR | |
| MA52421A (en) | PHARMACEUTICAL COMPOUNDS | |
| MA49421A (en) | RNA FORMULATIONS | |
| MA46339A (en) | CYANOPYRROLIDINE DERIVATIVES ACTIVATING AS USP 30 INHIBITORS | |
| MA48765A (en) | SULFONAMIDE SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | |
| MA49847A (en) | ENZYMATIC PRODUCTION OF HEXOSES | |
| DK3887360T3 (en) | MICROBIOCIDES THIAZOLE DERIVATIVES | |
| MA40770A (en) | MERGED IMIDAZOLES PENTACYCLIC DERIVATIVES | |
| MA40774A (en) | DIARYLEUREA DERIVATIVES AS KINASE P38 INHIBITORS | |
| MA54521A (en) | SUBSTITUTED OXOPYRIDINE DERIVATIVES | |
| DK3498278T3 (en) | Compounds for the treatment of diseases related to DUX4 expression | |
| MA45478A (en) | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | |
| FR3022462B1 (en) | ORAL COMPOSITION OF ANTI-TNFALPHA ANTIBODY | |
| FR3050174B1 (en) | COMBINATION FOR AQUATIC ACTIVITY | |
| FR3010147B1 (en) | ISOSTATICAL SUSPENSION OF A TURBOREACTOR BY DOUBLE REAR SUPPORT | |
| MA41198A (en) | ENZYMATIC ACTIVITY TESTS FOR I2S | |
| DK3826723T3 (en) | BORONIC ACID DERIVATIVES | |
| MA51795A (en) | OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B | |
| FR3014437B1 (en) | NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN | |
| MA49055A (en) | MERGED PENTACYCLIC IMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | |
| MA42048A (en) | AMINOESTERS DERIVATIVES | |
| MA56441A (en) | THIOPHENE SUBSTITUTED CARBOXAMIDES AND THEIR DERIVATIVES AS MICROBICIDES |